Sangamo Therapeutics (SGMO) Return on Invested Capital (2016 - 2025)
Sangamo Therapeutics (SGMO) has disclosed Return on Invested Capital for 9 consecutive years, with 30.08% as the latest value for Q4 2025.
- For Q4 2025, Return on Invested Capital rose 3343.0% year-over-year to 30.08%; the TTM value through Dec 2025 reached 30.08%, up 3343.0%, while the annual FY2025 figure was 28.39%, 2642.0% down from the prior year.
- Return on Invested Capital hit 30.08% in Q4 2025 for Sangamo Therapeutics, up from 8.4% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 30.08% in Q4 2025 and bottomed at 8.4% in Q3 2025.
- Average Return on Invested Capital over 5 years is 0.87%, with a median of 0.7% recorded in 2022.
- Year-over-year, Return on Invested Capital crashed -569bps in 2024 and then soared 3343bps in 2025.
- Sangamo Therapeutics' Return on Invested Capital stood at 0.47% in 2021, then tumbled by -42bps to 0.67% in 2022, then plummeted by -269bps to 2.47% in 2023, then crashed by -36bps to 3.35% in 2024, then skyrocketed by 997bps to 30.08% in 2025.
- According to Business Quant data, Return on Invested Capital over the past three periods came in at 30.08%, 8.4%, and 5.11% for Q4 2025, Q3 2025, and Q2 2025 respectively.